B+
Bull case
0%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
GKOS
GlaukosFNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The constructive case is that GKOS has already moved Epioxa from approval into commercial launch and secured a permanent J-code effective July 1, 2026, while the March 2026 investor presentation continued to position iDose TR and Epioxa as the company's two major growth drivers [#8-K-2026-03-02]. If Q1 commentary later confirms early launch traction, investors could lean back toward the roughly $134.8 median target in the packet.
Posture
Defensive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-09-10.
What can break
As of April 29, 2026 UTC, the scheduled Q1 2026 earnings release had not yet been confirmed from checked sources, leaving revenue, EPS, guidance, and market-reaction evidence unavailable for this run.
Momentum
84
Value
37
Sentiment
32
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $130.00 · Bull $145.00 · Bear $105.00Analysis 2026-04-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $197.15
Why
Momentum84 · Δ7d -6.2
Value37 · Δ7d -0.0
Sentiment32 · Δ7d +1.9
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 2 setup hits (3d) with net bullish as of 2026-09-10.
- • Sentiment remains the lead driver in the composite, 7D delta +1.9.
Contradictions & invalidation
- • As of April 29, 2026 UTC, the scheduled Q1 2026 earnings release had not yet been confirmed from checked sources, leaving revenue, EPS, guidance, and market-reaction evidence unavailable for this run.
- • Commercial success still depends on executing the launches of iDose TR and Epioxa, which management itself identifies as key growth drivers; any slower surgeon adoption, patient access friction, or reimbursement delays would pressure the thesis [#8-K-2026-03-02].
- • The cautious case is that this is still mainly a monitoring run: the earnings release itself was not yet available from checked sources as of April 29, 2026 UTC, so there is no confirmed beat/miss, no guidance revision, and no verified analyst target-reset signal yet.
Catalyst clock
2026-04-29
Q1 2026 earnings release is scheduled for April 29 after market close
Lead driver: Sentiment · See AI snapshot
Momentum
84
9% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
-9.4
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
32
62% active weight
Current posture
7d trendImproving
Δ7d
+1.9
Δ21d
+5.6
Why this grade
Composite grade F. Momentum 84.1 / Value 36.6 / Sentiment 31.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-29. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$130.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$10.95B
Beta
0.71
Shares Out
58.98M
P/E (TTM) · Derived
-56.6
P/S (TTM)
13.75
P/FCF (TTM) · Derived
-368.73
Rev YoY
+49.5%
EPS YoY
-9.1%
Gross Margin
+79.1%
Op Margin
-12.9%
Net Debt
-$172.22M
Current Ratio
5.04
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data